Johnson & Johnson is currently seeking a Physician Program Director to join our Abiomed Team for the Minneapolis/Denver territory.
About Johnson & Johnson: At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
For more than 130 years, diversity, equity & inclusion (DEI) has been a part of our cultural fabric at Johnson & Johnson. Our diverse workforce and culture of belonging accelerate innovation to solve the world’s most pressing healthcare challenges.
The Physician Program Director focuses on establishing formal Impella programs through sustainable relationships with account stakeholders and key opinion leaders (KOLs) in the field of hemodynamic support. The Physician Program Director represents all aspects of Abiomed and acts as a field liaison to connect hospitals to internal resources such as the medical office, research, marketing, and executive teams. The PPD will be responsible for partnering with hospitals to identify areas for program growth through best practice implementation, protocol development, and workflow improvement. The PPD will also support the commercial organization with peer-to-peer programs to translate clinical and program best practices.
Principal Duties and Responsibilities:
- Develop sustainable relationships with designated accounts, health systems, key opinion leaders, and stakeholders.
- Develop and manage Impella programs based on individual customer needs.
- Understand hospital market dynamics and deploy appropriate tools for efficiency and patient care.
- Present complex health economic information in an engaging and credible manner.
- Advocate on behalf of heart recovery programs to health system administration.
- Facilitate customer advisory boards for feedback on new products and evaluations.
- Identify and develop new key opinion leaders through various programs.
- Serve as a corporate liaison between Key Opinion Leaders, IDNs, Healthcare System leaders, and Abiomed’s Executive team.
- Execute and facilitate important customer meetings at major medical shows.
- Communicate routinely with all members of the sales and Abiomed leadership team.
Qualifications:
- BA/BS required. MBS or MBA preferred.
- 4 or more years of sales experience within Abiomed or >7 years of related industry sales experience.
- Prior KOL management experience or existing relationships in the geographic area.
- Must be able to travel overnight extensively (70% depending on geography) including weekends.
- Strong understanding of US health care policy and payment systems.
- Outstanding interpersonal skills to influence business objectives.
- Ability to balance strategic thinking with tactical execution.
- Demonstrates responsiveness and a sense of urgency.
- Ability to prioritize work and manage multiple priorities.
- Excellent written and oral communication skills.
- Mastery of cardiac anatomy and clinical data.
Johnson & Johnson is an Affirmative Action and Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, age, national origin, or protected veteran status and will not be discriminated against on the basis of disability.
The anticipated base pay range for this position is $131,000 to $210,450. This position is eligible for an annual performance bonus and a car allowance through the Company’s Fleet program.
Employees may be eligible to participate in various Company-sponsored employee benefit programs.
For additional general information on Company benefits, please go to: Johnson & Johnson Employee Benefits.
This job posting is anticipated to close on September 20, 2024. The Company may extend this time-period.
